118 related articles for article (PubMed ID: 10555125)
21. [Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
Wu WH; Li Q; Xu BH; Zhang P; Zhao LM; Yuan P; Wang JY; Cai RG; Zhou AP
Zhonghua Zhong Liu Za Zhi; 2008 Jul; 30(7):548-51. PubMed ID: 19062727
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer.
Fisherman JS; Cowan KH; Noone M; Denicoff A; Berg S; Poplack D; Balis F; Venzon D; McCabe M; Goldspiel B; Chow C; Ognibene FP; O'Shaughnessy J
J Clin Oncol; 1996 Mar; 14(3):774-82. PubMed ID: 8622023
[TBL] [Abstract][Full Text] [Related]
23. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
[TBL] [Abstract][Full Text] [Related]
24. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
J Clin Oncol; 1994 Feb; 12(2):241-8. PubMed ID: 7509380
[TBL] [Abstract][Full Text] [Related]
25. Dose-finding study of paclitaxel and cyclophosphamide in patients with advanced breast cancer.
Sessa C; Pagani O; Parma G; Goldhirsch A; Cavalli F
Semin Oncol; 1995 Jun; 22(3 Suppl 6):112-7. PubMed ID: 7541152
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of docetaxel and topotecan in patients with solid tumors.
Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
[TBL] [Abstract][Full Text] [Related]
27. Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor.
Kwasny W; Kornek G; Haider K; Valencak J; Ulrich-Pur H; Penz M; Lang F; Depisch D; Scheithauer W
Breast Cancer Res Treat; 2000 Oct; 63(3):235-41. PubMed ID: 11110057
[TBL] [Abstract][Full Text] [Related]
28. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
Millward MJ; Zalcberg J; Bishop JF; Webster LK; Zimet A; Rischin D; Toner GC; Laird J; Cosolo W; Urch M; Bruno R; Loret C; James R; Blanc C
J Clin Oncol; 1997 Feb; 15(2):750-8. PubMed ID: 9053501
[TBL] [Abstract][Full Text] [Related]
29. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
30. Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Becerra CR; Verma UN; Tran HT; Tavana D; Williams NS; Frenkel EP
Am J Clin Oncol; 2008 Jun; 31(3):219-25. PubMed ID: 18525298
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
[TBL] [Abstract][Full Text] [Related]
32. Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer.
Lalisang RI; Voest EE; Wils JA; Nortier JW; Erdkamp FL; Hillen HF; Wals J; Schouten HC; Blijham GH
Br J Cancer; 2000 Jun; 82(12):1914-9. PubMed ID: 10864197
[TBL] [Abstract][Full Text] [Related]
33. A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer.
Lauria R; Ferrari E; Tramontana S; Morabito A; Perrone F; Maffeo A; Fiorentino R; Casella G; Iodice F; Ricchi P; Carlomagno C; Varriale E; De Placido G; De Placido S; Bianco AR; Pignata S
Oncology; 1999; 56(4):267-73. PubMed ID: 10343189
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer.
Lück HJ; Du Bois A; Thomssen C; Lisboa B; Untch M; Köhler G; Hecker D
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):34-7. PubMed ID: 9144689
[TBL] [Abstract][Full Text] [Related]
35. Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
Nisticò C; Bria E; Cuppone F; Fornier M; Sperduti I; Carpino A; Pace A; Cognetti F; Terzoli E
Anticancer Drugs; 2007 Jul; 18(6):687-92. PubMed ID: 17762397
[TBL] [Abstract][Full Text] [Related]
36. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
Semin Oncol; 1994 Oct; 21(5 Suppl 8):9-14. PubMed ID: 7524159
[TBL] [Abstract][Full Text] [Related]
37. Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy.
Gregory RK; Hill ME; Moore J; A'Hern RP; Johnston SR; Blake P; Shephard J; Barton D; Gore ME
Eur J Cancer; 2000 Mar; 36(4):503-7. PubMed ID: 10717527
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
O'Reilly S; Fleming GF; Barker SD; Walczak JR; Bookman MA; McGuire WP; Schilder RJ; Alvarez RD; Armstrong DK; Horowitz IR; Ozols RF; Rowinsky EK
J Clin Oncol; 1997 Jan; 15(1):177-86. PubMed ID: 8996140
[TBL] [Abstract][Full Text] [Related]
39. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.
Basser RL; Sobol MM; Duggan G; Cebon J; Rosenthal MA; Mihaly G; Green MD
J Clin Oncol; 1994 Aug; 12(8):1659-66. PubMed ID: 8040678
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
